Skip to main content

Table 1 Association of PD-L1 staining with clinicopathologic factors in all patients without neoadjuvant chemotherapy

From: Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

 

TC

TCIC

IC

sTIL level

Factors

Negative

Positive

Fisher

Negative

Positive

Fisher

Negative

Positive

Fisher

Low

High

Fisher

N (%)

N (%)

P value

N (%)

N (%)

P value

N (%)

N (%)

P value

N (%)

N (%)

P value

Age

[N = 341]

 

[N = 340]

 

[N = 340]

 

[N = 345]

 

 < 50 years

81 (88)

11 (12)

0.5411

68 (75)

23 (25)

0.2256

71 (78)

20 (22)

0.1466

60 (63)

35 (37)

0.0153

 ≥ 50 years

226 (91)

23 (9)

 

202 (81)

47 (19)

 

211 (85)

38 (15)

 

191 (76)

59 (24)

 

Race/ethnicity

[N = 341]

 

[N = 340]

 

[N = 340]

 

[N = 345]

 

 Black

34 (83)

7 (17)

0.1159

20 (49)

21 (51)

< 0.0001

21 (51)

20 (49)

< 0.0001

17 (41)

24 (59)

< 0.0001

 White+Latino

257 (91)

24 (9)

 

235 (84)

45 (16)

 

246 (88)

34 (12)

 

219 (77)

66 (23)

 

 Others

16 (84)

3 (16)

 

15 (79)

4 (21)

 

15 (79)

4 (21)

 

15 (79)

4 (21)

 

Histologic type

[N = 340]

 

[N = 339]

 

[N = 339]

 

[N = 344]

 

 IDC

261 (90)

29 (10)

1

225 (78)

64 (22)

0.262

233 (81)

56 (19)

0.0121

200 (68)

92 (32)

< 0.0001

 ILC

34 (89)

4 (11)

 

34 (89)

4 (11)

 

37 (97)

1 (3)

 

36 (95)

2 (5)

 

 Metaplastic

0 (0)

0 (0)

 

0 (0)

0 (0)

 

0 (0)

0 (0)

 

0 (0)

0 (0)

 

 Mixed IDC/ILC

11 (92)

1 (8)

 

10 (83)

2 (17)

 

11 (92)

1 (8)

 

14 (100)

0 (0)

 

Histologic grade

[N = 340]

 

[N = 339]

 

[N = 339]

 

[N = 344]

 

 1 + 2

216 (96)

10 (4)

< 0.0001

200 (88)

26 (12)

< 0.0001

208 (92)

18(8)

< 0.0001

201 (87)

30 (13)

< 0.0001

 3

90 (79)

24 (21)

 

69 (61)

44 (39)

 

73 (65)

40 (35)

 

49 (43)

64 (57)

 

sTIL level

[N = 337]

 

[N = 337]

 

[N = 337]

 

NA

 

 < 10%

233 (95)

12 (5)

< 0.0001

226 (92)

19 (8)

< 0.0001

235 (96)

10 (4)

< 0.0001

   

 ≥ 10%

70 (76)

22 (24)

 

42 (46)

50 (54)

 

44 (48)

48 (52)

    

ER

[N = 341]

 

[N = 340]

 

[N = 340]

 

[N = 345]

 

 Negative

60 (86)

10 (14)

0.1828

46 (66)

24 (34)

0.0026

48 (69)

22 (31)

0.0011

27 (39)

43 (61)

< 0.0001

 Positive

247 (91)

24 (9)

 

224 (83)

46 (17)

 

234 (87)

36 (13)

 

224 (81)

51 (19)

 

PR

[N = 341]

 

[N = 340]

 

[N = 340]

 

[N = 342]

 

 Negative

95 (84)

18 (16)

0.0125

73 (65)

40 (35)

< 0.0001

78 (69)

35 (31)

< 0.0001

54 (48)

59 (52)

< 0.0001

 Positive

212 (93)

16 (7)

 

197 (87)

30 (13)

 

204 (90)

23 (10)

 

197 (85)

35 (15)

 

HER2

[N = 338]

 

[N = 337]

 

[N = 337]

 

[N = 342]

 

 Negative

278 (91)

29 (9)

0.2195

248 (81)

58 (19)

0.0178

257 (84)

49 (16)

0.0801

231 (75)

78 (25)

0.0071

 Positive

26 (84)

5 (16)

 

19 (61)

12 (39)

 

22 (71)

9 (29)

 

17 (52)

16 (48)

 

TNBC

[N = 338]

 

[N = 337]

 

[N = 337]

 

[N = 342]

 

 No

250 (90)

28 (10)

1

226 (81)

52 (19)

0.0518

238 (86)

40 (14)

0.0069

227 (80)

56 (20)

< 0.0001

 Yes

54 (90)

6 (10)

 

41 (69)

18 (31)

 

41 (69)

18 (31)

 

21 (36)

38 (64)

 

Receptor group

[N = 338]

 

[N = 337]

 

[N = 337]

 

[N = 342]

 

 ER/PR pos

224 (91)

23 (9)

0.4491

207 (84)

40 (16)

0.0022

216 (87)

31 (13)

0.0009

210 (84)

40 (16)

< 0.0001

 HER2

26 (84)

5 (16)

 

19 (61)

12 (39)

 

22 (71)

9 (29)

 

17 (52)

16 (48)

 

 TNBC

54 (90)

6 (10)

 

41 (69)

18 (31)

 

41 (69)

18 (31)

 

21 (36)

38 (64)

 

Tumor size

[N = 340]

 

[N = 339]

 

[N = 339]

 

[N = 344]

 

 ≤ 2 cm

176 (92)

16 (8)

0.34

157 (81)

36 (19)

0.3325

162 (84)

31 (16)

0.5449

151 (77)

46 (23)

0.0517

 > 2 to 5 cm

105 (87)

16 (13)

 

90 (75)

30 (25)

 

96 (80)

24 (20)

 

79 (65)

43 (35)

 

 > 5 cm

25 (93)

2 (7)

 

22 (85)

4 (15)

 

23 (88)

3 (12)

 

20 (80)

5 (20)

 

pN

[N = 338]

 

[N = 337]

 

[N = 337]

 

[N = 342]

 

 (y)pN0

207 (90)

22 (10)

0.4972

185 (80)

45 (20)

0.5121

191 (83)

39 (17)

0.882

169 (73)

62 (27)

0.9442

 (y)pN1

81 (91)

8 (9)

 

70 (80)

18 (20)

 

73 (83)

15 (17)

 

65 (71)

26 (29)

 

 (y)pN2

10 (91)

1 (9)

 

8 (73)

3 (27)

 

9 (82)

2 (18)

 

8 (67)

4 (33)

 

 (y)pN3

7 (78)

2 (22)

 

5 (63)

3 (38)

 

6(75)

2 (25)

 

6 (75)

2 (25)

 

pM

[N = 338]

 

[N = 337]

 

[N = 337]

 

[N = 342]

 

 0

301 (90)

32 (10)

0.4036

265 (80)

68 (20)

1

275 (83)

58 (17)

1

245 (72)

93 (28)

1

 1

4 (80)

1 (20)

 

3 (75)

1 (25)

 

4 (100)

0 (0)

 

3 (75)

1 (25)

 

pStage

[N = 336]

 

[N = 335]

 

[N = 335]

 

[N = 340]

 

 I

163 (92)

15 (8)

0.2829

150 (84)

29 (16)

0.1412

156 (87)

23 (13)

0.1034

142 (78)

40 (22)

0.0637

 II

111 (90)

13 (10)

 

92 (75)

31 (25)

 

95 (77)

28 (23)

 

80 (65)

44 (35)

 

 III

24 (83)

5 (17)

 

21 (72)

8 (28)

 

23 (79)

6 (21)

 

22 (73)

8 (27)

 

 IV

4 (80)

1 (20)

 

3 (75)

1 (25)

 

4 (100)

0 (0)

 

3 (75)

1 (25)

 
  1. IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, sTIL stromal tumor infiltrating lymphocytes, ER estrogen receptor, PR progesterone receptor, pos positive, TNBC triple-negative breast cancer